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Conclusions: Patients treated with an optimal treatment 
plan have 10% probability of experiencing treatment failure 
in terms of local recurrence or severe treatment related 
toxicity. In patients with suboptimal treatment plans the risk 
for treatment failure doubles. More, impact of dose volume 
constraints on the clinical results suggests that the highest 
priority in treatment planning should be given to reach the 
planning aims for the target dose coverage.  
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Purpose/Objective: Treatment of locally advanced cervical 
cancer involves multidisciplinary care using external beam 
radiotherapy, chemotherapy, brachytherapy, and surgery. We 
aimed to compare both tumor and treatment characteristics 
between with patients with complete pathologic response 
(CR) and patients with residual disease (RD). 
Materials and Methods: This monocentric restrospective 
study included 40 consecutive patients, treated with external 
beam radiotherapy, pulsed-dose-rate brachytherapy and 
completion surgery. Treatment planning was performed to 
obtain a cumulative D90 value for the intermediate-risk 
clinical target volume (IR-CTV) ≥ 60α/β=10. Different clinical 
and dosimetric parameters were analyzed and compared 
between patients with RD and those with CR. 
Results: We observed 18 (45%) patients with CR and 22 (55%) 
patients with RD. In univariate analysis, patients with RD had 
a significantly longer overall treatment time than those with 
CR (59.5 vs 53 days, p = 0.0321). The D90 value for the high-
risk CTV (HR-CTV) was higher in the group with CR than in the 
group with RD (65.9 vs 64.2Gyα/β=10, p = 0.0439). In 
multivariate analysis, overall treatment time remained the 
only predictive factor for CR (p = 0.033), even if the 
difference for D90 HR-CTV kept a trend toward significance (p 
= 0.057). 
Conclusions: This study showed that tumor sterilization is 
significantly correlated with overall treatment time and 
probably with cumulative dose delivered to the HR-CTV. 
These results emphasize the attention that must be given to 
treatment organization and dosimetry optimization.  
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Purpose/Objective: An ideal dosimeter for prostate 
brachytherapy should present high sensitivity, no 
dependencies on beam parameters, real-time and in-vivo 
dose measurement, independence of dose rate and 
temperature, dose linearity, tissue equivalence, be easy to 
use and calibrate, detectable in the anatomic volume to 
check its position, not expensive and with disposable use of 
its implantable part.  
Organic scintillating materials have been used for radiation 
detection for decades. Despite of the low density of these 
materials, their fast response and near water equivalence 
make them suitable for in-vivo and real-time dosimetry. We 
evaluated the performance of these materials under regimes 
such as the ones found in prostate Low Dose Rate (LDR) and 
High Dose Rate (HDR) brachytherapy. 
We developed a scintillator fiber optic dosimeter in two 
configurations suitable for both LDR and HDR prostate 
brachytherapy comprising two disposable probes adapted to 
both modalities. 
LDR typically uses low energy emitters (< 50 keV) and for that 
reason a high sensitivity device is required. Our detector uses 
a 5mm scintillating fiber optic optically coupled to a fiber 
optic waveguide with a silicon photomultiplier (SiPM) for light 
readout. SiPMs are solid-state devices, comprising multiple 
pixels that behave as Geiger-mode avalanche photodiode 
detectors individually. These devices allow the development 
of lower cost dosimetric devices but because they present a 
characteristic dark noise, we developed a patented solution 
to overcome this issue. 
On the other hand, HDR uses radiation with energies above 
the Cherenkov threshold for organic materials. This means 
that a blue light is present as a form of noise when a charged 
particle travels through the medium with a velocity higher 
than the velocity of light in that material.  
Materials and Methods: The scintillating fiber optic used is a 
BCF-12 (Saint-Gobain) optically coupled to a PMMA 1 mm core 
fiber optic (Avago Techonologies). The SiPM used is a 1mm2 
Multi-Pixel Photon Counter (MPPC) from Hamamatsu. 
Results: The dosimeter shows a linear response with dose and 
is capable of detecting mGy dose variations like an ionization 
chamber. Besides fulfilling all the requirements for a 
dosimeter in brachytherapy, the high sensitivity of this 
device makes it a suitable candidate for application in LDR-
brachytherapy. Energy linearity for energies below 50 keV 
using monochromatic x-ray photons will be presented.  
Conclusions: Clinical in-vitro tests were performed in 
collaboration with two Portuguese public hospitals and 
results from both LDR and HDR studies will be presented.  
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Purpose/Objective: We intend to show technical aspects of 
the treatment of facial and thoracic skin lesions with high 
dose rate (HDR) plesiotherapy. 
Materials and Methods: Eighteen treatments in sixteen 
patients with sarcoma, basal cell and squamous cell 
carcinoma in facial region (12) and cutaneous metastasis of 
breast cancer in thoracic region (6) were performed. Facial 
